Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 4

Pharmacogenomics and Personalized Medicine


Archive: Volume 4, 2011

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Pharmacogenomics and Personalized Medicine 2011, 4:137-145

Published Date: 17 November 2011

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

Cavallari LH, Jeong H, Bress A

Pharmacogenomics and Personalized Medicine 2011, 4:123-136

Published Date: 7 November 2011

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Tang W, Hu Z, Muallem H, Gulley ML

Pharmacogenomics and Personalized Medicine 2011, 4:95-107

Published Date: 8 September 2011

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain

Wallace TJM, Zai CC, Brandl EJ, Müller DJ

Pharmacogenomics and Personalized Medicine 2011, 4:83-93

Published Date: 18 August 2011

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Vaezi A, Feldman CH, Niedernhofer LJ

Pharmacogenomics and Personalized Medicine 2011, 4:47-63

Published Date: 20 July 2011

A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

Gelinas R, Chesler EJ, Vasconcelos D, Miller DR, Yuan Y, Wang K, Galas D

Pharmacogenomics and Personalized Medicine 2011, 4:35-45

Published Date: 4 July 2011

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, et al

Pharmacogenomics and Personalized Medicine 2011, 4:1-9

Published Date: 14 March 2011